CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment
Clinical Snapshot
PICO Framework
| P — Population | Patients with obesity |
| I — Intervention | CagriSema (combination of semaglutide and cagrilintide) |
| C — Comparator | Semaglutide monotherapy or placebo |
| O — Outcomes | Percent weight loss, absolute weight loss, waist circumference, systolic blood pressure, gastrointestinal adverse events |
Bottom Line
This meta-analysis of four RCTs (n=4,419) suggests CagriSema, a combination of semaglutide and cagrilintide, produces superior weight loss compared to semaglutide monotherapy or placebo in obesity patients. The treatment achieved an additional 11 kg weight loss and meaningful reductions in waist circumference and blood pressure. However, the extremely high heterogeneity (I² = 94.8%) significantly undermines confidence in these pooled estimates, suggesting substantial differences between studies that weren't adequately explored. Gastrointestinal adverse events were more frequent with CagriSema. While the large effect size appears promising, the statistical heterogeneity, limited long-term data, and increased side effect profile warrant cautious interpretation. Clinicians should await individual patient data meta-analyses and longer-term safety studies before considering this combination therapy. The evidence currently appears insufficient to definitively change clinical practice.
Key Findings
P Value: Not reported
Effect Size: Cohen's d: -1.38 (large effect size)
Primary Outcome: Percent weight loss
Nnt Or Sensitivity: Mean difference: -11 kg absolute weight loss compared to controls
Confidence Interval: 95% CI: -1.84 to -0.91
Clinical Application
Limited by high cost, potential side effects, and need for specialist monitoring Would require TGA approval and PBS listing consideration; aligns with RACGP obesity management guidelines emphasising multimodal approaches Adults with obesity seeking pharmacological weight management
Abstract
The obesity epidemic is a major health burden that enhances susceptibility to a broad spectrum of metabolic-associated comorbidities, ranging from fatty liver disease and endocrine dysfunction to traditional risks like type 2 diabetes mellitus and cardiovascular disease. Glucagon-like peptide-1 receptor agonists, including semaglutide, facilitate weight loss alongside glucose metabolism. The dual therapy CagriSema, which combines semaglutide with cagrilintide was developed. We systematically searched MEDLINE (via PubMed), Web of Science, Scopus, and Cochrane Library, from inception to July 2025, for randomized controlled trials (RCTs) comparing CagriSema with semaglutide monotherapy or placebo in patients with obesity. Four RCTs (n = 4,419) were included (CagriSema: 3,055; control: 1,364). Pooled analysis showed that CagriSema significantly reduced percent weight loss (Cohen's d: -1.38; 95% CI: -1.84 to -0.91; I² = 94.8%). CagriSema also resulted in greater absolute weight loss (MD: -11 kg), waist circumference (MD: -9.41 cm), and systolic blood pressure (MD: -7.06 mmHg). Gastrointestinal adverse events were more frequent (RR: 1.32). CagriSema therapy was associated with superior weight reduction compared with semaglutide or placebo. In conclusion, CagriSema achieves greater weight loss than semaglutide or placebo but increases gastrointestinal adverse events, warranting careful tolerability monitoring and longer-term data.
References
- 1.Gadelmawla, A. F., Hammad, N., Atta, K., Diaa, A., Abouzkaly, F., Soni, K., Kelkar, R., Agrawal, S. P., Ahmed, R., Jain, H., Passey, S., & Aronow, W. S. (2026). CagriSema versus semaglutide monotherapy or placebo for obesity: A systematic review and meta-analysis of randomized controlled trials with GRADE assessment. *The American Journal of Cardiology*. https://doi.org/10.1016/j.amjcard.2026.02.030
Related Research
European journal of radiology
A CT-based deep learning model to differentiate between benign and malignant adrenal lesions
3 Aug 2026
Journal of chemical information and modeling
A Unified Molecular Graph and Protein Language Model Framework for Predicting Human Drug-Hormone Receptor Interactions with Structure-Aware Validation
28 July 2026
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Differential effects of hormone therapy formulations on Parkinson's disease risk: a systematic review and meta-analysis
23 July 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service